Akito Fukuda

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC.

Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti-Programmed Cell Death Protein 1 in SCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 03, 2025

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

Journal: Journal for immunotherapy of cancer

Published: November 17, 2025

KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer.

KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer.

Journal: International immunology

Published: August 18, 2025

Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing.

Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing.

Journal: Japanese journal of clinical oncology

Published: October 20, 2024

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 31, 2023

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.

Journal: Journal of cancer research and clinical oncology

Published: October 29, 2023

Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.

Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.

Journal: Expert review of anticancer therapy

Published: September 29, 2023

Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan.

Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan.

Journal: Anticancer research

Published: December 18, 2022

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.

Journal: Cancer science

Published: June 16, 2022

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis.

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis.

Journal: Frontiers in oncology

Published: September 19, 2021

Correction to: An analysis of the radiological factors associated with respiratory failure in COVID-19 pneumonia and the CT features among different age categories.

Correction to: An analysis of the radiological factors associated with respiratory failure in COVID-19 pneumonia and the CT features among different age categories.

Journal: Japanese journal of radiology

Published: August 13, 2021

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.

Journal: Translational lung cancer research

Published: June 03, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026